Clinical Trials Directory

Trials / Completed

CompletedNCT01940341

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
426 (actual)
Sponsor
Gilead Sciences · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B virus (HBV) infection.

Detailed description

Study GS-US-320-0108 is a multi-center clinical trial, planned to enroll participants in multiple countries, including China. However, due to the review timeline difference in China, full enrollment was reached in the main study before China was able to participate. Therefore, details for the China cohort was registered separately (NCT02836236) on ClinicalTrials.gov as the China cohort will not be part of the main study analysis.

Conditions

Interventions

TypeNameDescription
DRUGTAF25 mg tablet administered orally once daily
DRUGTDF300 mg tablet administered orally once daily
DRUGTAF PlaceboTablet administered orally once daily
DRUGTDF PlaceboTablet administered orally once daily

Timeline

Start date
2013-09-12
Primary completion
2015-09-30
Completion
2022-08-31
First posted
2013-09-12
Last updated
2023-09-25
Results posted
2017-03-30

Locations

105 sites across 17 countries: United States, Australia, Canada, France, Hong Kong, India, Italy, Japan, New Zealand, Poland, Romania, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom

Source: ClinicalTrials.gov record NCT01940341. Inclusion in this directory is not an endorsement.

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hep (NCT01940341) · Clinical Trials Directory